(CercleFinance.com) – AstraZeneca announced Monday that the FDA had approved the use of its immunotherapy Imfinzi for the treatment of advanced or recurrent endometrial cancer.
The biopharmaceutical laboratory specifies that the green light from the American health authority relates more specifically to endometrial cancer characterized by a failure of the DNA repair system (dMMR).
AstraZeneca highlights that endometrial cancer is today the fourth most common cancer among women in the United States, with 66,000 cases diagnosed each year and nearly 12,000 deaths.
In individuals with an advanced form of the disease, the five-year survival rate is now less than 20%.
In a statement, AstraZeneca said the FDA approval followed a Phase III clinical study that showed a 58% reduction in disease progression or death in patients treated with Imfinzi.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
